The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | An overview of the management of patients with R/R Waldenström’s macroglobulinemia
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the management of patients with relapsed/refractory (R/R) Waldenström’s macroglobulinemia (WM). These patients can be divided into two groups: those who relapse after chemoimmunotherapy and those who are resistant or who relapse after BTK inhibitors (BTKis). For the former, a switch to BTKis, such as ibrutinib or acalabrutinib, is common. For the latter, BCL2-targeted agents such as venetoclax, non-covalent BTKis, chemotherapy, or CAR T-cells are all options. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
